You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Lundbeck does not control content on third-party websites and cannot make representations concerning the accuracy of information on every website you visit. Lundbeck is not responsible for the privacy policy of any third-party website. We encourage you to read the privacy policy of every website you visit.



Our Value Chain

From Idea to Patient

Developing innovative and safe treatments is complex. It takes approximately 10-15 years for a new drug to move through the pharmaceutical value chain from when an idea is conceived until an approved treatment is made available to patients.


In Research, we identify new disease targets and establish and confirm an understanding of the mechanism of action for new, safe drug candidates. Researching new treatments requires deep insight into the disease and into the unmet medical needs of patients. Researchers work to understand the underlying disease biology and identify new targets in the brain. New substances are then selected based on efficacy and are tested for safety and tolerability, before being selected for drug development. 

Drug Development

In Drug Development, we conduct clinical studies globally to establish evidence for new drug candidates, we engage healthcare specialists in scientific discussions to enhance the understanding of our clinical results, and we work to develop safe, reliable and efficient manufacturing processes. Safeguarding the rights, safety and wellbeing of study participants is of the greatest importance. 


We conduct ongoing monitoring to evaluate the safety, quality and effectiveness of our products and we continuously inform regulatory authorities about our activities and findings. The reporting of potential adverse drug reactions by healthcare professionals and patients is very important to continuously evaluate the benefits and risks of our products allowing us to take proactive action as warranted. 


The production process has three major stages: Chemical Production where the Active Pharmaceutical Ingredient (API) is made; Pharmaceutical Bulk Production where the product is produced; and the Finished Goods Production where the packs are assembled. We strive to create the best supply chain in the pharmaceutical industry through continuous improvement of reliability, quality and cost. Every year, more than 100 million finished goods are sent to distributors, wholesalers and hospitals through close collaboration with our sales affiliates globally. 


Our products are registered globally in more than 100 countries. We produce and conduct scientific and promotional events to educate HCPs about the safe and effective use of our products. We engage decision-makers in activities to help them prioritize psychiatric and neurological disorders and argue the societal value of our products based on thorough assessments. 


In Sales, we inform and educate the key stakeholders who are responsible for managing treatment with prescription drugs. We have sales representatives in more than 50 countries. Our activities towards healthcare professionals aim to ensure a correct understanding of our products and their use. We also engage experts and leading specialists as speakers for educational events, where information is exchanged with the purpose of enhancing patient care. 


Development of our medicines often continues after the initial marketing approval. Based on our knowledge of the molecules we often seek to study them in a range of indications where we believe them to have a potential effect. We dedicate significant time and resources to ensure that we develop our medicines to the full extent of their medical potential.

More from lundbeck


Our products - the proud results of years of research.


Take your next career step with Lundbeck.


Lundbeck remains committed to sustainability through our strong strategy.